BIOMARKERS FOR PREDICTING RESPONSE TO A CANCER VACCINE

(19)

(11)

EP 2 601 529 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	25.01.2017 Bulletin 2017/04

(45)	Mention of the grant of the patent:
	21.12.2016 Bulletin 2016/51

(21)	Application number: 11749629.9

(22)	Date of filing: 05.08.2011

(51)

International Patent Classification (IPC):

G01N 33/574^(2006.01)

(86)	International application number:
	PCT/US2011/046799

(87)	International publication number:
	WO 2012/019125 (09.02.2012 Gazette 2012/06)

(54)	BIOMARKERS FOR PREDICTING RESPONSE TO A CANCER VACCINE BIOMARKER FÜR DIE VORHERSAGE DER REAKTION AUF EINE KREBSVAKZINE BIOMARQUEURS DE PRÉDICITION DE DE LA RÉPONSE D'UN VACCIN ANTICANCÉREUX

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

17.02.2011 US 201161443955 P
06.08.2010 US 371537 P

(43)	Date of publication of application:
	12.06.2013 Bulletin 2013/24

(60)	Divisional application:
	16199473.6

(73)	Proprietor: The United States of America, as represented by The Secretary, Department of Health and Human Services
	Bethesda, Maryland 20892-7660 (US)

(72)	Inventors:
	GILDERSLEEVE, Jeffrey Frederick Maryland 21703 (US) CAMPBELL, Christopher Baltimore Maryland 21217 (US) OYELARAN, Oyindasola North Adams Massachusetts 01247 (US) GULLEY, James Takoma Park Maryland 20912 (US) SCHLOM, Jeffrey Potomac Maryland 20854 (US)

(74)	Representative: Grünecker Patent- und Rechtsanwälte PartG mbB
	Leopoldstraße 4 80802 München 80802 München (DE)

(56)

References cited: :

US-A1- 2004 151 733

HELEN ZHANG ET AL: "Antibodies against GD2 Ganglioside Can Eradicate Syngeneic Cancer Micrometastases", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 58, no. 13, 1 July 1998 (1998-07-01), pages 2844-2849, XP007912414, ISSN: 0008-5472
LIVINGSTON P O ET AL: "Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII OCT 1997 LNKD- PUBMED:9353421, vol. 45, no. 1, October 1997 (1997-10), pages 1-9, XP002666026, ISSN: 0340-7004
GESZNER P ET AL: "Enhanced activity of CMP-NeuAc:Galbeta1-4GlcNAc:alpha2,6-sialyl transf erase in metastasizing human colorectal tumor tissue and serum of tumor patients", CANCER LETTERS, NEW YORK, NY, US, vol. 75, no. 3, 20 December 1993 (1993-12-20), pages 143-149, XP023162722, ISSN: 0304-3835, DOI: 10.1016/0304-3835(93)90056-F [retrieved on 1993-12-20]
ZHANG YALONG ET AL: "Multidimensional glycan arrays for enhanced antibody profiling", MOLECULAR BIOSYSTEMS, vol. 6, no. 9, 2010, pages 1583-1591, ISSN: 1742-206X(print)
Y. ZHANG ET AL: 'Supporting Information for Multidimensional glycan Arrays for Enhanced Antibody Profiling', [Online] 2010, Online Retrieved from the Internet: <URL:http://www.rsc.org/suppdata/mb/c0/c002 259d/c002259d_esi.pdf> [retrieved on 2012-11-20]
CAMPBELL CHRISTOPHER T ET AL: "Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF", CLINICAL CANCER RESEARCH, vol. 19, no. 5, March 2013 (2013-03), pages 1290-1299, ISSN: 1078-0432(print)
CAMPBELL ET AL: 'supplementary table 2, Serum antibodies to Blood Group Antigen A Predict Survival on PROSTVAC-VF', [Online] 29 January 2013, online Retrieved from the Internet: <URL:http://clincancerres.aacrjournals.org/ content/suppl/2012/12/31/1078-0432.CCR-12-2 478.DC1/tab2.pdf> [retrieved on 2013-11-21]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).